We are expecting doses of AstraZeneca in Q2, and once that regulatory approval has been obtained, we will be able to ascertain the delivery schedule with the supplier. I will ask my deputy minister here if he would like to step in and clarify anything else, but I will say that there are variables that we need to take into account.
In addition to these AstraZeneca doses, under our bilateral agreement we are scouring the globe for additional doses of AstraZeneca that we can bring into the country as soon as possible. That is why we opted into the COVAX doses, for AstraZeneca.
The other G7 countries already have doses of AstraZeneca. That was not something that they chose to do. We are also going to work with our supplier itself, to move up those doses as soon as possible. Those variables are really important to take into account.
I'll hand it over to Bill Matthews.